Tanvex BioPharma, Inc. (TPE:6541)
50.70
-0.90 (-1.74%)
Sep 9, 2025, 1:30 PM CST
Tanvex BioPharma Revenue
Tanvex BioPharma had revenue of 46.82M TWD in the quarter ending June 30, 2025, with 175.28% growth. This brings the company's revenue in the last twelve months to 110.99M, up 221.19% year-over-year. In the year 2024, Tanvex BioPharma had annual revenue of 34.68M, down -43.53%.
Revenue (ttm)
110.99M
Revenue Growth
+221.19%
P/S Ratio
108.94
Revenue / Employee
560.58K
Employees
198
Market Cap
12.09B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
Dec 31, 2020 | 300.00K | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Lumosa Therapeutics | 37.25M |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Pell Bio-Med Technology | 27.43M |